NEW YORK (GenomeWeb News) — GNI and Auckland UniServices today today said they will work together to map gene regulatory networks for melanoma and breast cancer.
According to the partners, the effort will also study how the networks are affected as patients respond to various anti-cancer drugs. GNI and UniServices will co-own the intellectual property resulting from the three-year collaboration and GNI will lead the effort to commercialize it, the companies said.
GNI, a Japanese biopharmaceutical company, will provide its technology and reagents to produce the gene networks. In addition, some data analysis will be done at GNI's Systems Pharmacology Research Institute in Fukuoka.
The collaboration is supported by grants from New Zealand Health Research Council's International Investment Opportunities Fund and New Zealand's Breast Cancer Research Trust.
Auckland UniServices is the commercial arm of the University of Aukland.